用α-2b干扰素治疗慢性乙型肝炎。

Treatment of chronic hepatitis B with interferon alfa-2b.

作者信息

Müller R, Baumgarten R, Markus R, Schulz M, Wittenberg H, Hintsche-Kilger B, Fengler J D, Von Wussow P, Meisel H, Klein H

机构信息

Abteilung für Gastroenterologie und Hepatologie, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Federal Republic of Germany.

出版信息

J Hepatol. 1990;11 Suppl 1:S137-40. doi: 10.1016/0168-8278(90)90181-p.

DOI:10.1016/0168-8278(90)90181-p

PMID:2079572

Abstract

A total of 58 patients with histologically confirmed chronic viral hepatitis B and presence of hepatitis B surface antigen and hepatitis B virus DNA (HBV DNA) in the serum were randomized in a prospectively controlled trial. Thirty patients were treated with 3 megaunits of recombinant interferon alfa-2b (INTRON A, R Schering-Plough, Essex Corporation) subcutaneously thrice weekly for 4 months. Twenty-eight controls received no treatment. The post-treatment follow-up period consisted of 6 months. Twenty-eight treated patients and 27 controls completed the protocol. One female patient of the treatment group showed a complete response, and eight other treated patients (32%) showed a partial response to therapy. Three patients in the control group (11%) lost hepatitis B e antigen and HBV DNA spontaneously. This finding is statistically significant (p less than 0.05). The elimination of hepatitis B virus markers from the serum was associated with a normalization of aminotransferase activities in the serum. Reactivation of hepatitis was not observed after seroconversion.

摘要

在一项前瞻性对照试验中，共有58例经组织学确诊为慢性乙型病毒性肝炎且血清中存在乙型肝炎表面抗原和乙型肝炎病毒DNA（HBV DNA）的患者被随机分组。30例患者接受重组干扰素α-2b（英特龙A，R先灵葆雅公司，埃塞克斯公司）300万单位皮下注射，每周3次，共4个月。28例对照未接受治疗。治疗后的随访期为6个月。28例接受治疗的患者和27例对照完成了方案。治疗组的1例女性患者显示完全缓解，其他8例接受治疗的患者（32%）显示对治疗部分缓解。对照组的3例患者（11%）自发丢失乙型肝炎e抗原和HBV DNA。这一发现具有统计学意义（p<0.05）。血清中乙型肝炎病毒标志物的消除与血清转氨酶活性的正常化相关。血清转换后未观察到肝炎再激活。